VEA
GYRE icon

Virtus ETF Advisers’s Gyre Therapeutics GYRE Stock Holding History

Virtus ETF Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,389
Closed -$193K – 343
2018
Q3 		$193K Sell
2,389
-1,752
-42% -$139K 0.02% 195
2018
Q2 		$362K Buy
+4,141
New +$726K 0.32% 137

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Virtus ETF Advisers's GYRE Position: Q4 2018 in Review

Virtus ETF Advisers sold out of Gyre Therapeutics (GYRE) in Q4 2018, closing a stake of 2,389 shares — an estimated $193K sold.

Virtus ETF Advisers first reported a position in GYRE in Q2 2018 and held it in 2 quarters. The position peaked at $362K in Q2 2018. 65 funds tracked by Wall St. Rank hold GYRE as of Q4 2018.

  • Virtus ETF Advisers reported no remaining Gyre Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,389 Gyre Therapeutics shares in Q4 2018, an estimated $193K.
  • Virtus ETF Advisers first reported a position in Gyre Therapeutics in Q2 2018 and held it in 2 quarters.
  • Virtus ETF Advisers's Gyre Therapeutics position peaked at $362K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2018.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.